NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
Clinical Trials
11 trialsNCT00006421 2026-03-13
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
National Institutes of Health Clinical Center (CC)
Completed
NCT05710328 2026-03-02
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06502691 2026-03-02
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT07285993 2026-02-13
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT04016818 2026-02-10
Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution
Stanford University
Phase EARLY_PHASE1 Not yet recruiting
NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT04316117 2026-01-26
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting